Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
-
- Health & Fitness
-
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology.
Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com.
Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
-
Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.
Key Timestamps
01:04 - Guest Introduction
03:45 - FDA Indication for Obesity
08:45 - SURMOUNT-2
17:40 - SURMOUNT-3 and -4
22:00 - Future of Incretin Therapies -
SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD
In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies.
Chapters:
00:35 - Guest Introduction
01:10 - SELECT Results Overview
04:25 - Next Steps for Research
07:15 - Mechanism of Action for CV Benefit
09:00 - FLOW Trial Implications
11:25 - Impact on Access
15:00 - Future of Incretin Therapies
21:45 - Predicting the Next 5-10 Years for Semaglutide -
Understanding MARD, Comparing Popular CGM Sensors
In this episode, the hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.
Video version: https://www.hcplive.com/view/diabetes-dialogue-understanding-mard-comparing-popular-cgm-sensors
Key Highlights:
00:35 - The Myth of MARD
04:10 - Considerations When Interpreting MARD
10:15 - FreeStyle Libre 3 vs. Dexcom G7 -
ATTD 2024 Preview
In the episode, hosts provide insight into sessions to watch, device news they are excited for, what makes ATTD a unique and valuable experience for the diabetes care team, and how the meeting’s annual yearbook session encapsulates the exciting developments within the field.
Video Version: https://www.hcplive.com/view/diabetes-dialogue-attd-2024-preview
Key Highlights:
01:05 - Bellini’s ATTD Picks
03:45 - Isaacs’ ATTD Picks
06:20 - Health Disparities in Focus
07:10 - Time in Tighter Range
10:20 - Insulin Users with T2D
11:15 - ATTD Yearbook Session -
Time in Range, CGM Metrics for Predicting Outcomes in Diabetes
The introduction of CGM in 1999 completely shifted the trajectory of care for people with diabetes. Now, new data suggest advanced CGM metrics, such as time in range, are proving comparable to HbA1c for predicting diabetic retinopathy and other microvascular outcomes.
In this episode, Viral Shah, MD, joins Diabetes Dialogue to discuss a recent study examining associations between time in range and other advanced CGM metrics with diabetic retinopathy and the implications for use in predicting other microvascular outcomes.
Episode Timestamps
00:05 - Intro
02:04 - CGM Data to Predict Diabetes Complications
05:15 - Time in Range and Microvascular Complications
09:36 - Glycemic Variability and Incident Diabetic Retinopathy
12:17 - Time in Range, CGM Data for Predicting CV Outcomes -
Tirzepatide in Type 1 Diabetes, with Viral Shah, MD
In this episode, hosts are joined by Shah for a discussion on his recent proof-of-concept study looking at tirzepatide in type 1 diabetes, the prospect of GLP-1 RA-based therapies in type 1 diabetes, and the potential roles for tirzepatide beyond T2D and weight management.
Episode Highlights
00:00 - Intro
01:56 - Use of GLP-1s in T1D
05:32 - Study on Tirzepatide in T1D
10:04 - Insulin Use in Study
11:20 - Safety Outcomes
Customer Reviews
Excellent podcast!
Highly recommend for people living with diabetes! Thanks so much for the technology updates and diabetes management info you provide! :)